Authors : Dr. Shweta Swaroop

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/3hhny36y

Scribd : https://tinyurl.com/jzecj256

DOI : https://doi.org/10.38124/ijisrt/26aug609

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background Patients living with chronic kidney disease typically require complex medication regimens to manage both their declining renal function and the constellation of associated conditions including hypertension, anaemia, and mineral bone disorders. This pharmacological complexity creates substantial opportunities for drug-drug interactions, dosing errors, and inappropriate prescribing. The progressive loss of kidney function alters drug pharmacokinetics unpredictably, making dose adjustments essential yet frequently overlooked in clinical practice. This study aimed to evaluate prescribing patterns, assess the appropriateness of dose adjustments relative to renal function, and identify medication errors among CKD patients through systematic Drug Use Evaluation and Drug Utilization Review methodologies.

References :

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72 =).
2. 2.Borg R, Carlson N, Søndergaard J, et al. The growing challenge of chronic kidney disease: an overview of current knowledge. Int J Nephrol. 2023).
3. Evans PD, Taal MW. Epidemiology and causes of chronic kidney disease. Medicine. 2011;39(7):402-6.)
4. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150. doi:10.1038/kisup.2012.73.),
5. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154-62.
6. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47.)
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1): S1-S266.)
8. World Health Organization: Burden of Disease Project. Available from: http://www3.who.int/whosis/menu.cfm)
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Ann Intern Med. 2003;139:137–47) (11 Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory hemodialysis patients: A pooled analysis Am J Kidney Dis. 2005;46:669–80)
10. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease And Pharmacotherapy. 2004;38:853–8).
11. Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory haemodialysis patients: A pooled analysis. Am J Kidney Dis. 2005;46:669–80
12. Mayne KJ, Sardell RJ, Staplin N, et al. Frailty, multimorbidity, and polypharmacy. Clin J Am Soc Nephrol. 2024.
13. Alruqayba WS, Paudyal V, Malcolm P, et al. Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study. J Pharm Policy Pract. 2024.
14. Lambourg EJ, et al. Stopping versus continuing metformin in patients with advanced CKD: a nationwide Scottish target trial emulation study. Am J Kidney Dis. 2025;85:196-204.